Skip to main content
. Author manuscript; available in PMC: 2022 Dec 20.
Published in final edited form as: J Am Coll Cardiol. 2021 Nov 16;78(20):2004–2012. doi: 10.1016/j.jacc.2021.08.064

Figure 3. Clinical Effect of Dapagliflozin by Background Medical Therapy.

Figure 3.

In the DAPA-HF trial, benefits of dapagliflozin on cardiovascular mortality or worsening HF were incremental and consistent regardless of background medical therapy for HFrEF. Modified with permission from Docherty KF et al.(25)